PriceTargets.com logo

Vigil Neuroscience - VIGL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.75
  • Forecasted Upside: 87.69%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$9.99 As of 03/30/2023 01:00 AM ET
▼ -0.41 (-3.94%)

This chart shows the closing price for VIGL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vigil Neuroscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIGL

Analyst Price Target is $18.75
▲ +87.69% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Vigil Neuroscience in the last 3 months. The average price target is $18.75, with a high forecast of $24.00 and a low forecast of $13.00. The average price target represents a 87.69% upside from the last price of $9.99.

This chart shows the closing price for VIGL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Vigil Neuroscience.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/30/2023MizuhoInitiated CoverageBuyLow
3/27/2023Morgan StanleyBoost TargetEqual Weight$12.00 ➝ $13.00Low
3/22/2023HC WainwrightReiterated RatingBuy$24.00Low
11/14/2022Morgan StanleyBoost TargetEqual Weight$11.00 ➝ $12.00Low
11/11/2022GuggenheimLower TargetBuy$22.00 ➝ $19.00Low
9/15/2022WedbushInitiated CoverageOutperform$19.00Low
8/29/2022HC WainwrightInitiated CoverageBuy$24.00Low
2/1/2022Morgan StanleyInitiated CoverageEqual Weight$17.00High
2/1/2022GuggenheimInitiated CoverageBuy$23.00High
2/1/2022Stifel NicolausInitiated CoverageBuy$24.00High
2/1/2022Jefferies Financial GroupInitiated CoverageBuy$20.00High
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Vigil Neuroscience logo
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.
Read More

Today's Range

Now: $9.99
Low: $9.86
High: $10.61

50 Day Range

MA: $11.11
Low: $8.77
High: $12.70

52 Week Range

Now: $9.99
Low: $2.18
High: $16.77

Volume

27,660 shs

Average Volume

19,686 shs

Market Capitalization

$356.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Vigil Neuroscience?

The following Wall Street research analysts have issued research reports on Vigil Neuroscience in the last twelve months: Guggenheim, HC Wainwright, Mizuho, Morgan Stanley, and Wedbush.
View the latest analyst ratings for VIGL.

What is the current price target for Vigil Neuroscience?

4 Wall Street analysts have set twelve-month price targets for Vigil Neuroscience in the last year. Their average twelve-month price target is $18.75, suggesting a possible upside of 87.7%. HC Wainwright has the highest price target set, predicting VIGL will reach $24.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $13.00 for Vigil Neuroscience in the next year.
View the latest price targets for VIGL.

What is the current consensus analyst rating for Vigil Neuroscience?

Vigil Neuroscience currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VIGL will outperform the market and that investors should add to their positions of Vigil Neuroscience.
View the latest ratings for VIGL.

What other companies compete with Vigil Neuroscience?

Other companies that are similar to Vigil Neuroscience include Monte Rosa Therapeutics, AlloVir, Ambrx Biopharma, Aura Biosciences and Tarsus Pharmaceuticals. Learn More about companies similar to Vigil Neuroscience.

How do I contact Vigil Neuroscience's investor relations team?

The company's listed phone number is 857-254-4445 and its investor relations email address is [email protected] The official website for Vigil Neuroscience is vigilneuro.com. Learn More about contacing Vigil Neuroscience investor relations.